ORCID: https://orcid.org/0000-0003-3930-4354; Höglinger, Günter U.
ORCID: https://orcid.org/0000-0001-7587-6187 und Dewachter, Ilse
(2025):
The evolving landscape of Alzheimer’s disease therapy: From Aβ to tau.
In: Cell, Bd. 188, Nr. 26: S. 7337-7354
[PDF, 7MB]
Abstract
A marked evolution in Alzheimer’s disease (AD) therapy research is ongoing. In this perspective, we highlight emerging outcomes of tau-targeting approaches with disease-modifying potential evidenced by PET-based slowing of tau accumulation and early signs of cognitive benefit. We outline how decades of iterative amyloid β (Aβ)-trial refinement leading to the recent successes of approved anti-Aβ therapies have set the stage for accelerated optimization of next-generation trials. We summarize key learnings from first-generation tau immunotherapies and how these paved the way for early achievements in tau trials, while many challenges remain. Finally, we discuss the back-translation of clinical outcomes into fundamental insights on human tau pathobiology, and we outline challenges and future directions for AD therapy development including combination therapy and targets beyond Aβ/tau. Together, this provides a framework for next-generation AD and tau-therapy development toward increasingly efficient disease-halting interventions.
| Dokumententyp: | Zeitschriftenartikel |
|---|---|
| EU Funded Grant Agreement Number: | 101053962 |
| Fakultät: | Medizin > Munich Cluster for Systems Neurology (SyNergy)
Medizin > Klinikum der LMU München > Neurologische Klinik und Poliklinik mit Friedrich-Baur-Institut |
| Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
| URN: | urn:nbn:de:bvb:19-epub-131254-3 |
| ISSN: | 00928674 |
| Sprache: | Englisch |
| Dokumenten ID: | 131254 |
| Datum der Veröffentlichung auf Open Access LMU: | 20. Jan. 2026 13:38 |
| Letzte Änderungen: | 20. Jan. 2026 13:38 |
| DFG: | Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198 |
